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S U M M A R Y
Anti-tuberculosis drug treatment is known to affect the number, phenotype, and effector functionality of
antigen-speciﬁc T-cells. In order to objectively gauge Mycobacterium tuberculosis (MTB)-speciﬁc CD8+ T-
cells at the single-cell level, we developed soluble major histocompatibility complex (MHC) class I
multimers/peptide multimers, which allow analysis of antigen-speciﬁc T-cells without ex vivo
manipulation or functional tests. We constructed 38 MHC class I multimers covering some of the most
frequent MHC class I alleles (HLA-A*02:01, A*24:02, A*30:01, A*30:02, A*68:01, B*58:01, and C*07:01)
pertinent to a South African or Zambian population, and presenting the following MTB-derived peptides:
the early expressed secreted antigens TB10.4 (Rv0288), Ag85B (Rv1886c), and ESAT-6 (Rv3875), as well
as intracellular enzymes, i.e., glycosyltransferase 1 (Rv2957), glycosyltransferase 2 (Rv2958c), and
cyclopropane fatty acid synthase (Rv0447c). Anti-TB treatment appeared to impact on the frequency of
multimer-positive CD8+ T-cells, with a general decrease after 6 months of therapy. Also, a reduction in
the total central memory CD8+ T-cell frequencies, as well as the antigen-speciﬁc compartment in
CD45RACCR7+ T-cells was observed. We discuss our ﬁndings on the basis of differential dynamics of
MTB-speciﬁc T-cell frequencies, impact of MTB antigen load on T-cell phenotype, and antigen-speciﬁc T-
cell responses in tuberculosis.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Cell-mediated immune responses are essential for protection
against tuberculosis (TB).1 CD8+ T-cells produce cytotoxic
molecules as well as cytokines. Cytotoxic T-cells are capable of
killing cells infected with Mycobacterium tuberculosis (MTB),2while
aiding the recruitment and activation of other immune cell types.
CD8+ T-cells recognize short antigen-derived peptides (epitopes)
presented on major histocompatibility complex (MHC) class I
molecules on the surface of antigen-presenting cells (APCs).3
Clinical and preclinical assessment of CD8+ T-cells in TB show that* Corresponding author. Tel.: +46 708627566.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).CD8+ T-cells play an important role in recall responses, as well as in
long-term protection to MTB infection.2,4
Only a limited number of T-cell epitopes of 9–11 amino acids in
length have been identiﬁed to date,5 using technologies such as
ELISA,6 ELISPOT,7 the chromium release assay,8 the thymidine
incorporation assay,9 intracellular cytokine staining (ICS),10 and
soluble MHC class I/peptide multimers.11 A large number of these
epitopes originate from only a few well-characterized, immunologi-
cally relevant MTB proteins, e.g., early-secreted antigenic target
6 kDa (ESAT-6, Rv3875),12 culture ﬁltrate protein 10 kDa (CFP10,
Rv3874),7 antigen 85B (Ag85B, Rv1886c),11 TB10.4 (Rv0288),13 and a
conserved transmembrane protein (Rv1733c).14 This represents a
rather biased view of T-cell responses to only a handful of over
4000 existing MTB proteins potentially expressed during infection.15
From another 60 MTB proteins, one or only several T-cell epitopesciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
R. Axelsson-Robertson et al. / International Journal of Infectious Diseases 32 (2015) 23–2924have been identiﬁed – leaving the majority of the MTB proteome to
be explored for T-cell responses.
Since the expression of MTB proteins is associated with
different stages of MTB growth as well as TB disease,16 the
identiﬁcation of a broader MTB epitope proﬁle is essential for the
discovery of markers associated with active or latent TB infection
(LTBI). Half of the MTB epitopes associate with a single MHC class I
allele (HLA-A*02:01) out of more than 3000 different alleles
described in humans thus far.17 Based on this information, it is
clear that more CD8+ T-cell epitopes derived from novel MTB
antigens associating with clinically relevant MHC class I alleles need
to be described, especially since the regional distribution of alleles
varies between continents as well as different ethnic groups.18
One technique to identify epitope-speciﬁc (MTB antigen-
speciﬁc) T-cells without in vitro manipulation is the use of MHC
class I multimers. We have previously designed a broad panel of
MHC class I multimers covering seven different MHC alleles
presenting epitopes from six different MTB-derived proteins:19 the
early expressed secreted antigens TB10.4 (Rv0288), Ag85B
(Rv1886c), and ESAT-6 (Rv3875), as well as intracellular enzymes
glycosyltransferase 1 (Rv2957), glycosyltransferase 2 (Rv2958c),
and cyclopropane fatty acid synthase (CFA synthase; Rv0447c).
Since anti-TB drug treatment is known to affect the number,
phenotype, and effector functionality of antigen-speciﬁc CD8+
T-cells,20,21 we chose to develop and work with MHC class I
multimers in this study as a means to decipher the nature of antigen-
speciﬁc CD8+ T-cells before and after anti-TB drug therapy.
2. Materials and methods
2.1. Patient data
Seven HIV patients with untreated, active pulmonary TB,
diagnosed with at least two positive sputum smears for acid-fast
bacilli or positive sputum culture for MTB, were enrolled at the
University of Stellenbosch, South Africa, as well as from the
University Hospital Lusaka, Zambia. Five were female and two
were male; they ranged in age from 20 to 55 years. Samples were
taken at the time of diagnosis (before initiating treatment) and
after 6 months of treatment (end of therapy for drug-sensitive TB).
Peripheral blood mononuclear cells (PBMCs) were acquired from
the patient after receiving their informed consent, as well as
endorsement from the institutional review boards (No. N05/11/
187; Health Research and Ethics Committee, Stellenbosch Univer-
sity). Frozen PBMCs were shipped to Sweden where they were
HLA-typed using sequence-speciﬁc primer (SSP) typing kits (One
Lambda Inc., Canoga Park, CA, USA). Ethical consent was also
obtained from the ethics committee in Stockholm (Ref. 2011/863-
31/2, including the samples from Zambia).
2.2. Cellular analysis with multimers
Thirty-eight ﬂuorescently labelled multimers (streptavidin–
phycoerythrin (PE), streptavidin-allophycocyanin (APC), and
ﬂuorescein isothiocyanate (FITC)) covering HLA-A*02:01,
A*24:02, A*30:01, A*30:02, A*68:01, B*58:01, and C*07:01
presenting peptides from the MTB-derived proteins Rv0288,
Rv1886c, Rv3875, Rv2958c, Rv2957, and Rv0447c, were either
constructed in-house (as previously described22) or commercially
acquired (Beckman Coulter, San Diego, USA, and Immudex,
Copenhagen, Denmark). In the CD3+CD8+CD4 compartment,
multimer-positive events were recorded using anti-CD3-PE/Texas
red (ECD) (Clone UCHT1; Beckman Coulter), anti-CD4-Paciﬁc
orange (Clone S3.5; Invitrogen, Carlsbad, CA, USA), and anti-CD8a-
APC/Cy7 (Clone SK1; Becton Dickinson, Franklin Lakes, NJ, USA).
Cells in the CD3+CD8CD4+ compartment were excluded fromenumeration of multimer-positive events. All cellular analyses
were performed using a FACS Gallios Flow-cytometer (Beckman
Coulter). Only multimer responses that were at least three times
higher than the negative control and for which we could detect
more than 50 events were analyzed further.
2.3. Phenotypic analysis of the T-cells
Analysis of the phenotype, degranulation marker (CD107a), and
survival marker (interleukin 7 receptor subunit alpha, IL7Ra)
expression proﬁle of the multimer-speciﬁc cells was performed
using anti-CD45RA-PerCP/Cy5.5 (Clone HI100; Biolegend, San
Diego, CA, USA), anti-CCR7-PE/Cy7 (Clone 3D12; Becton Dick-
inson), anti-CD107a-Paciﬁc blue (PB) (Clone H4A3; Biolegend), and
anti-CD127-APC/Alexa-700 (Clone R34.34; Beckman Coulter).
2.4. Statistical analysis
The Student’s t-test or paired t-test was applied for the analysis
of statistical signiﬁcance between different T-cell populations
using GraphPad Prism 4.0 software (GraphPad Inc., La Jolla, CA,
USA). A p-value of less than 0.05 was considered signiﬁcant.
3. Results
3.1. Multimeric analysis of selected TB epitopes
We successfully constructed 38 MHC class I MTB peptide-loaded
multimers covering some of the most frequently occurring MHC class
I alleles (HLA-A*02:01, A*24:02, A*30:01, A*30:02, A*68:01, B*58:01,
and C*07:01) among South African and Zambian populations. The
multimers were tested on samples obtained from seven HLA-typed
individuals diagnosed with acute pulmonary TB, prior to and post
anti-TB treatment. The antigen-speciﬁc anti-TB responses by CD8+
T-cells were generally low but diverse before and after treatment.
Furthermore, the frequencies of antigen-speciﬁc CD8+ T-cells ranged
between 0 and 2.2% before treatment, while the frequencies were
found to range between 0 and 1.8% post anti-TB therapy (Table 1).
On average, the frequencies decreased signiﬁcantly from 0.25%
before treatment to 0.20% after treatment (p = 0.02) (Figure 1A),
but the trend varied considerably between individual antigen-
speciﬁc T-cell populations (Figure 1B). Anti-TB treatment resulted
in only a limited decrease in frequencies of antigen-speciﬁc CD8+
T-cells for most multimer-speciﬁc populations. However, for a few
multimer-speciﬁc populations, a dramatic decrease in frequencies
could be observed, e.g., A2-TB10.4IMYNYPAML (D 0.77%), A24-
ESAT6ELNNALQNL (D 0.54%), and B58-Ag85BQTYKWETFL (D 0.34%).
Despite an observed decrease in frequencies in the majority of
antigen-speciﬁc CD8+ T-cell populations, an increase in antigen-
speciﬁc T-cell frequencies could be observed post treatment with
regard to some populations, e.g., T-cells directed against A2-
Ag85BFIYAGSLSA, A24-Ag85BIYAGSLSAL, and A68-TB10.4ANTMAMMAR
(Table 1). The average decrease in frequencies after anti-TB
treatment was independent of allele-restricted and peptide-
derived TB proteins. However, some T-cell populations restricted
by certain HLA alleles exhibited the tendency for more dramatic
decreases in T-cell frequencies post anti-TB treatment, e.g.,
B*58:01 (D 0.34%) and A*24:02 (D 0.12%). A decrease in frequency
could also be observed with respect to antigen-speciﬁc T-cell
populations recognizing peptides derived from the early expressed
TB antigens (TB10.4, Ag85B, and ESAT-6) (D 0.11%) (Figure 1C) as
compared to the glycosyltransferases and CFA synthase (D 0.01%)
(Figure 1D). The decrease in frequencies for most multimer-
speciﬁc populations was also true (Supplementary Material,
Figure S1), despite the fact that some individuals (PAT1 and PAT4)
Table 1
Prevalence of epitope-speciﬁc T-cells identiﬁed by multimer staininga
Tetramer/patient 1 2 3 4 5 6 7
Bef Aft Bef Aft Bef Aft Bef Aft Bef Aft Bef Aft Bef Aft
Neg PE 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1
Neg APC 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1
A2-TB10.4IMYNYPAML 0.8 0.1 1.0 0.2
A2-TB10.4AMLGHAGDM 0.2 0.1 0.1 0.2
A2-TB10.4MLGHAGDMA 0.3 0.0 0.1 0.1
A2-Ag85BYLLDGLRAQ 0.0 0.1 0.3 0.5
A2-Ag85BKLVANNTRL 0.2 0.2 1.4 0.9
A2-Ag85BFIYAGSLSA 0.0 0.4 0.0 0.1
A2-ESAT6AMASTEGNV 0.1 0.1 0.4 0.4
A2-ESAT6LLDEGKQSL 0.0 0.1 0.0 0.1
A2-Rv2958ALADLPVTV 0.0 0.0 0.0 ND
A2-Rv2957SIIIPTLNV 0.2 0.1 0.0 0.1
A2-Rv0447VLAGSVDEL 0.0 0.1 0.0 ND
A24-TB10.4IMYNYPAML 0.4 0.0 0.3 0.1
A24-Ag85BWYYQSGLSI 0.2 0.2 0.5 0.3
A24-Ag85BFLTSELPQW 0.9 0.0 0.1 0.1
A24-Ag85BIYAGSLSAL 0.0 0.4 0.0 0.0
A24-ESAT6AYQGVQQKW 0.0 0.0 0.1 0.1
A24-ESAT6ELNNALQNL 1.9 1.2 2.2 1.8
A24-Rv2958KYIAADRKI 0.0 0.0 0.0 0.1
A24-Rv2957PYNLRYRVL 0.3 0.1 0.1 0.4
A24-Rv0447KYIFPGGLL 0.0 0.0 0.0 0.1
A3001-TB10.4QIMYNYPAM 0.3 0.2 0.2 0.1
A3001-TB10.4LVRAYHAMS 0.2 0.2 0.5 0.3
A3001-Rv2957IVLVRRWPK 0.1 0.2 0.3 0.3
A3002-TB10.4QIMYNYPAM 0.3 0.2 0.2 0.4
A3002-TB10.4IMYNYPAML 0.7 0.2 0.2 0.2
A3002-TB10.4AMEDLVRAY 0.2 0.2 0.3 0.1
A3002-ESAT6AMASTEGNV 0.1 0.1
A3002-Rv2958SARLAGIPY 0.5 0.2 0.8 0.6
A3002-Rv0447RMWELYLAY 0.1 0.2 0.3 0.2
A68-TB10.4HAMSSTHEA 0.3 0.2
A68-TB10.4ANTMAMMAR 0.1 0.2
A68-Ag85BLPQWLSANR 0.2 0.1
A68-Ag85BWGAQLNAMK 0.2 0.1
A68-Rv2958AAPEPVARR 0.2 0.1
A68-Rv2957LVYGDVIMR 0.0 0.2
A68-Rv0447AASAAIANR 0.0 0.0
B58-Ag85BQTYKWETFL 0.0 0.0 0.0 0.0 1.1 0.1
Cw07-Ag85BANNTRLWVY 0.0 0.0 0.1 0.0
Bef, before therapy; Aft, after therapy; PE, streptavidin–phycoerythrin; APC, streptavidin–allophycocyanin; ND, not determined; PBMC, peripheral blood mononuclear cells;
TB, tuberculosis; MHC, major histocompatibility complex.
a PBMCs from individuals with TB were incubated with MHC-matched MHC class I TB multimers and stained for T-cell markers. Results are reported as the percentage
multimer-positive events in the CD3+CD8+ T-cell population; negative gating was performed to exclude CD4+ T-cells. Negative multimers were included to decipher the
background staining. For shaded points it was possible to retrieve the phenotype as well as data regarding the degranulation marker CCR7 and the survival marker CD127 of
the antigen-speciﬁc T-cells.
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treatment (information not shown).
3.2. Phenotypic analysis of antigen-speciﬁc T-cells
Phenotypic analyses of total CD8+ T-cells as well as the antigen-
speciﬁc T-cell compartment based on CD45RA and CCR7 expression
were performed to gauge differences before and after anti-TB
treatment. In general, the majority of total as well as antigen-
speciﬁc CD8+ T-cells belonged to the precursor compartment
(CD45RA+CCR7+), followed by terminally differentiated
(CD45RA+CCR7) and effector memory cells (CD45RACCR7).
Importantly, the frequencies of these populations did not differ
considerably prior to and post anti-TB treatment. The central
memory T-cell compartment (CD45RACCR7+) decreased signiﬁ-
cantly post anti-TB treatment, both among total CD8+ T-cells
(p = 0.04) and antigen-speciﬁc T-cell populations (p = 0.008)
(Figure 2). The frequencies of antigen-speciﬁc CD8+ T-cells
belonging to a certain phenotype (based on CD45RA/CCR7
expression) were independent of the presenting HLA allele and
the antigen-derived MTB epitope (data not shown).3.3. Analysis of degranulation and survival markers
IL7Ra is an important marker for T-cell survival, and this
receptor can normally be found on most mature T-cells.23 No
difference could be detected in terms of IL7Ra (also known as
CD127) expression among total CD8+ T-cells prior to (80%) and
post treatment (78%). However, a signiﬁcant decrease in IL7Ra was
detected among antigen-speciﬁc T-cells (88% vs. 83%; p = 0.04)
(Figure 3A and B).
CD8+ T-cell cytotoxicity can be correlated with the expression
of the degranulation marker CD107a (LAMP-1).24 The expression of
CD107a was generally upregulated on antigen-speciﬁc T-cells
compared to the total CD8+ T-cell population. A trend of decreased
frequencies of CD107a expression post-treatment could be seen
among total CD8+ T-cells, while the opposite was true for the
antigen-speciﬁc CD8+ T-cell populations (Figure 3C and D).
4. Discussion
The use of a broad panel of 38 different multimers presenting
peptides from different MTB-derived proteins in this study allowed
Figure 1. Frequency percentages of multimer-positive CD8+ T-cells. (A) Average detection of antigen-speciﬁc CD8+ T-cells in blood from patients before anti-TB treatment
and after 6 months of completed treatment. (B) The trend of each of the 38 antigen-speciﬁc T-cell populations detected by different multimers before and after anti-TB
treatment in the CD8+ T-cell compartment. The average percentage of multimer-speciﬁc CD8+ T-cells before and after anti-TB treatment recognizing epitopes derived from
(C) the previously well-studied antigens TB10.4 (Rv0288), Ag85B (Rv1886c), and ESAT-6 (Rv3875), and from (D) the newly discovered TB antigens glycosyltransferase
1 (Rv2958c), glycosyltransferase 2 (Rv2957), and CFA synthase (Rv0447c). The two-sided Student’s t-test was performed and signiﬁcant values were calculated based on
p-values; *p < 0.05. (Bef, before therapy; Aft, after therapy.)
R. Axelsson-Robertson et al. / International Journal of Infectious Diseases 32 (2015) 23–2926us to characterize the TB-speciﬁc CD8+ T-cell repertoire before and
after (6 months) anti-TB treatment in patients from countries
endemic for TB.25 Since the importance of CD8+ T-cells has been
increasingly acknowledged, e.g., in combination with anti-tumour
necrosis factor alpha (anti-TNF-a) treatment,26 it is important to
further characterize the CD8+ T-cell-mediated immune response
in patients with active TB, and identify the hitherto unknown effect
of anti-TB treatment on antigen-speciﬁc T-cell populations thereof.Figure 2. Frequencies of the (A) total CD8+ T-cells, and (B) antigen-speciﬁc CD8+ T-cell
central memory (CD45RACCR7+), horizontal lines; effector memory (CD45RACCR7
anti-TB treatment (naı¨ve (CD45RA+CCR7+), chequered; central memory (CD45RACCR7+
cells (CD45RA+CCR7), black). The two-sided Student’s t-test was performed and signiﬁ
after therapy.)The effect of anti-TB treatment concerning the frequency,
phenotype, and effector functions of antigen-speciﬁc CD8+ T-cells
has been studied previously in different settings, involving adults
and children with active TB.2,10,21,27,28 However, the respective
outcomes of these studies have been conﬂicting. In the current
report, the decreased frequencies of the antigen-speciﬁc CD8+
T-cells detected after TB treatment were contradictory to data
reported by other groups evaluating TB-speciﬁc multimer stainings expressing different phenotypic markers before (naı¨ve (CD45RA+CCR7+), dotted;
), diagonal lines; terminally differentiated cells (CD45RA+CCR7), white) and after
), vertical lines; effector memory (CD45RACCR7), grey; terminally differentiated
cant values were calculated based on p-values; *p < 0.05. (Bef, before therapy; Aft,
Figure 3. Frequencies of (A) total CD8+ T-cells, and (B) antigen-speciﬁc CD8+ T-cells expressing the CD127 (IL7Ra) cell-surface marker before and after anti-TB therapy.
Frequencies of (C) total CD8+ T-cells, and (D) antigen-speciﬁc CD8+ T-cells expressing the CD107a (LAMP-1) degranulation marker before and after anti-TB therapy. The
two-sided Student’s t-test was performed and signiﬁcant values were calculated based on p-values; *p < 0.05. (Bef, before therapy; Aft, after therapy.)
R. Axelsson-Robertson et al. / International Journal of Infectious Diseases 32 (2015) 23–29 27prior to and post anti-TB treatment. One reason for this might be
the low patient number included in our study (n = 7), but also other
points are worth discussing. One study described an increase in the
frequency of Ag85A-speciﬁc CD8+ T-cells (0.4%) at 4 months post
treatment in children using MHC class I multimers.20 The same
group also described a similar trend in antigen-speciﬁc T-cells
(speciﬁc for the 16 kDa antigen, Rv1490 and ESAT-6) derived from
MTB-infected adults. However, the results are not conclusive since
the frequencies of antigen-speciﬁc CD8+ T-cells recognizing
peptides derived from other TB antigens (Hsp65, Ag85B, and
Rv1614) show similar or reduced frequencies of antigen-speciﬁc
T-cells post anti-TB treatment.10 Also, a decrease in antigen-
speciﬁc CD4+ T-cells could be seen post anti-TB treatment using
HLA-DR8 multimers presenting ESAT-6-derived peptides.29 Since
our study shows a decrease in frequency of antigen-speciﬁc CD8+
T-cells particularly directed against the highly-expressed early
antigens TB10.4, Ag85B, and ESAT-6, the decrease might be a result
of reduced antigenic load during/after treatment (discussed
below). However, this and other studies implementing MTB-
speciﬁc MHC class I multimers, suggest that there appears be a
broad anti-TB CD8+ T-cell response involving many different
epitopes derived from different groups of TB proteins, albeit at a
very low frequency.10,19
The phenotype of the total CD8+ T-cell and antigen-speciﬁc
populations therein showed a similar pattern in our study, with a
signiﬁcant decrease in the central memory population post TB
treatment. Furthermore, the size of the other phenotypic CD8+ T-
cell compartments was not affected by anti-TB treatment. In line
with our ﬁndings, a report published last year attested to the
informative role of CD8+ T-cells in sensing bacterial burden in
patients who had undergone standard anti-TB treatment. Since
CD8+ T-cells recognize and respond to intrinsic (intracellular)antigens, the authors claimed that a declining CD8+ T-cell response
may be indicative of diminishing MTB populations due to anti-TB
drug therapy.21 Nonetheless, our current report is the ﬁrst study to
shed light on CD8+ T-cells speciﬁc for several TB epitopes based on
multimer staining.
Another important point is whether mycobacterial burden in
the patient affects the maintenance of antigen-speciﬁc memory
CD8+ T-cell numbers. In an evaluation by Theron and colleagues of
the longitudinal T-cell reactivity of South African TB patients using
interferon gamma release assays (IGRAs) such as TSPOT.TB,
QuantiFERON Gold In-tube, and PPD-ELISpot in the backdrop of
anti-TB treatment, mycobacterial load in sputum was found not to
correlate with the amount of interferon gamma (IFN-g) secreted by
the patients’ PBMCs.30 Although IGRAs largely account for MTB-
speciﬁc CD4+ T-cell responses in the periphery,31 CD8+ T-cells also
contribute with IFN-g secretion in response to stimulation with
epitopes from the same antigens.32 Patients with TB who were
culture-positive for MTB at the time of diagnosis and converted
after 6 months of anti-TB treatment did not exhibit differences in
IFN-g levels. The authors concluded that cellular immune
responses, at least in part, are not directly affected by MTB load
in patients in high-burden countries for TB. A more recent study by
Rozot et al. evaluated the cytokine proﬁle of CD4+ and CD8+ T-cell
response in patients with active TB as well as those with LTBI,
originating from various high-burden countries for TB. Similar to
the study by Theron and colleagues, MTB culture positivity was
shown not to affect the antigen-speciﬁc T-cell response of the
patients, while polyfunctionality was postulated as a reliable
diagnostic measure of the disease state.27 Nevertheless, TB
serodiagnostic tests do not account for qualitative variations in
TCR (T-cell receptor) speciﬁcities arising from different clusters of
MTB antigens occurring in the patient following anti-TB treatment.
R. Axelsson-Robertson et al. / International Journal of Infectious Diseases 32 (2015) 23–2928Several reasons may explain the different results concerning
the number of antigen-speciﬁc T-cells in the course of TB therapy.
The patient’s genetic background, which reﬂects the predomi-
nantly expressed HLA alleles in a given population, determines
which MTB epitopes the CD8+ T-cells are able to encounter and
respond to. Other factors are the molecular modiﬁcations
harboured by the MTB strain(s) infecting the individual, bioavail-
ability of MTB-derived factors, and previous bacille Calmette–
Gue´rin (BCG) vaccination, as well as contact with environmental
mycobacteria that play a fundamental role in shaping the TCR
antigen speciﬁcity repertoire.33,34 These phenomena impose
continuous exposure of the infected individual to antigenic stress,
collectively contributing to counter-modulation of T-cell func-
tionality – and quality of responsiveness of individual T-cells. High
rates of MTB transmission in high-burden countries for TB such as
South Africa and Zambia is another inevitable factor that inﬂuences
the diversity of CD8+ T-cell-dependent antigen recognition and the
ensuing effector response.25 It is important to appreciate that
geographical variation and disease endemicity are critical param-
eters that affect anti-TB CD4+ and CD8+ T-cell responses observed
in the population, a phenomenon that has been termed ‘antigenic
editing of the T-cell repertoire’ in the cancer ﬁeld.35
High antigen concentration in an individual prior to initiation of
therapy may induce the generation of potentially high numbers of
antigen-speciﬁc T-cells, given that MTB bacillary load in a patient
with pulmonary TB can reach 109 viable bacteria based on sputum-
smear microscopy and culture.36 As mentioned earlier, the
majority of drug-sensitive MTB bacilli are killed in the process
of anti-TB treatment, sparing only those that undergo metabolic
and physiological adaptation and become refractory to antibio-
tics.37 This serves as an indication of antigen turnover in the
patient, shaping the repertoire while inﬂuencing shifts in
bioavailability of MTB epitopes presented in association with
their MHC class I/II background together with pro-inﬂammatory
cytokines. Furthermore, there is a lack of knowledge concerning
whether anti-TB treatment drives surviving MTB bacilli to a latent
(dormant) state in humans, such as that observed in the Cornell
mouse model of TB.37,38 Thus, the signiﬁcant reduction in
mycobacterial load due to either bacillary death or dormancy
following anti-TB therapy is likely to alter the antigen recognition
repertoire of available T-cells. The remarkable reduction in
frequencies of IL7Ra-expressing antigen-speciﬁc CD8+ T-cells
after anti-TB therapy supports this notion. Therefore, some
populations of antigen-speciﬁc T-cells that were initially primed
by productive infection are possibly deprived of their cognate
antigenic target(s) after anti-TB therapy, resulting in T-cell death in
the long run.39
A noteworthy point is the ﬁtness and functionality of the
T-cells themselves. The T-cell response to stimuli can be
impaired in the event of excessive inﬂammation or anergy,
due to the downregulation of CD3 zeta chain expression, which
directly affects TCR activation.40 A similar phenomenon has
already been observed in pulmonary TB and leprosy where T-cell
activity could be restored with the addition of exogenous
interleukin 2 (IL-2).41 Since pulmonary TB is a disease
characterized by a largely TNF-a-driven, tissue-destructive,
hyper-inﬂammatory environment in the lung,16 the quality of
antigen-speciﬁc T-cell responses is inevitably perturbed. This
has very recently been reconﬁrmed in patients with active TB
who present with a large proportion of TNF-a single-positive
CD4+ T-cells in peripheral blood.27 Besides downregulation of
expression, delayed recruitment of the CD3 zeta chain to the TCR
complex owing to binding of low-afﬁnity antigen also contrib-
utes to reduced CD8+ T-cell functionality.42
The fact that the central memory CD8+ T-cell frequencies in
blood signiﬁcantly declined following anti-TB therapy couldimply that these cells home to tissue or organ compartments.
Okhrimenko and colleagues recently showed that the bone
marrow harbours resting memory CD4+ and CD8+ T-cells alike,
thus establishing a niche for long-term memory T-cells.43 Homing of
antigen-experienced memory CD8+ T-cells to the lung following
anti-TB therapy is still under debate, considering that active human
TB granulomas do not harbour functional CD8+ T-cell popula-
tions.44,45 Indeed, terminally differentiated CD45RA+CCR7 CD8+
T-cells have been associated with host-protective immune
responses in LTBI.10 These ﬁndings suggest that the lack of functional
CD8+ T-cells in active TB granulomas may, in part, be responsible for
decreased immune surveillance. If anti-TB therapy prompts
enhanced trafﬁcking of MTB-speciﬁc memory CD8+ T-cells to tissue
compartments, it may justify why their numbers in peripheral blood
decreased with time.
In conclusion, our ﬁndings suggest that anti-TB therapy might
alter the quality of CD8+ T-cell responses, based on the changes in
antigen recognition. This is a crucial observation – anti-TB
treatment may indirectly tailor the cellular immune compartment
to better manage the disease. Our report provides a view of
antigen-speciﬁc CD8+ T-cell populations that can in larger studies
be used to evaluate and longitudinally monitor the effectiveness of
anti-TB treatment and vaccine efﬁcacy trials. This also applies to
the assessment of novel host-directed therapies for TB, where the
assessment of the quality of targeted and protective anti-MTB
immune responses is desirable.
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